Point72 Hong Kong Ltd acquired a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,000 shares of the exchange traded fund’s stock, valued at approximately $296,000.
Several other institutional investors also recently modified their holdings of the company. Tidemark LLC boosted its position in shares of SPDR S&P Biotech ETF by 101.5% during the 3rd quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock valued at $39,000 after acquiring an additional 199 shares in the last quarter. ORG Partners LLC bought a new position in SPDR S&P Biotech ETF during the second quarter worth about $40,000. Quintet Private Bank Europe S.A. acquired a new stake in SPDR S&P Biotech ETF during the third quarter valued at approximately $40,000. ORG Wealth Partners LLC bought a new stake in shares of SPDR S&P Biotech ETF in the 3rd quarter valued at approximately $44,000. Finally, Howe & Rusling Inc. acquired a new position in shares of SPDR S&P Biotech ETF in the 3rd quarter worth approximately $49,000.
SPDR S&P Biotech ETF Price Performance
Shares of XBI stock opened at $99.31 on Tuesday. The stock’s fifty day simple moving average is $98.22 and its 200 day simple moving average is $96.64. SPDR S&P Biotech ETF has a one year low of $77.21 and a one year high of $105.47. The firm has a market cap of $7.57 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- Investing in the High PE Growth Stocks
- How to Master Trading Discipline: Overcome Emotional Challenges
- EV Stocks and How to Profit from Them
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- 3 Monster Growth Stocks to Buy Now
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.